The Antitumor Immunity and Tumor Responses of Chemotherapy with or without DC-CIK for Non-Small-Cell Lung Cancer in China: A Meta-Analysis of 28 Randomized Controlled Trials

Table 1

Characteristics of included studies.

First author, year	NSCLC				Interventions			Criteria	Detecting	Time	O
	Stage	E/C	M/F	Years	Cells	Usage	C
Xu, Y., 2010 [46]	III–IV	38/40	57/21	47–75	DC-CIK cells	CIK: 1.3–1.610^9/time (IV); DC (IC); 8–10 times/cycle, 2 cycles	NP	RECIST	FCM	4 w	O1, O2
Sheng, C., 2011 [47]	III-IV	32/33	37/28	35–65	DC-CIK cells	510^9/time, 4 times/cycle, 2 cycles (IV)	NP	WHO	FCM	2 w	O1, O2
Yuan, J., 2011 [48]	Advanced	34/34	42/26	Unclear	DC-CIK cells	Unclear, 4 times/cycle, 1 cycle (IV)	Chemo	WHO	Unclear	4 w	O1, O2
He, J., 2012 [49]	III–IV	31/31	Unclear	33–75	DC-CIK cells	Unclear, 2 times/cycle, 2 cycles (IV)	NP	WHO	Unclear	After	O1, O2
Peng, D., 2012 [50]	IIIa–IV	24/23	29/18	65–79	DC-CIK cells	DC: 1–1010^9/time, CIK: 1–20^1011/time, 2–3 times, 1 cycle (IV)	ALIMTA	RECIST	FCM	After	O1, O2
Shi, S. B., 2012 [51]	IIIb–IV	30/30	35/25	40–77	Ag-DC-CIK cells	DC: -, 4 times (SI); CIK: -, 5 times, 1 cycle (IV)	DP, GP	Unclear	FCM	After	O1, O2
Zhao, L., 2013[52]	IIIb–IV	36/36	Unclear	60–80	DC-CIK cells	Unclear, 3 times/cycle, 2 cycles (IV)	DP	RECIST	FCM	After	O1, O2
Zhu, Y., 2013 [53]	IIIb–IV	30/31	32/29	44–72	Ag-DC-CIK cells	Unclear, 4 times/cycle, 1cycle (IV)	TP	No	FCM	After	O1
Han, W., 2014 [54]	Advanced	42/23	45/20	Unclear	DC-CIK cells	510^9/time, 4 times/cycle, 4 cycles (IV)	DP	WHO	Unclear	After	O1, O2
Niu, B., 2014 [55]	III–IV	30/30	Unclear	32–77	DC-CIK cells	Unclear, 3 times/cycle, 1 cycle (IV)	GP	RECIST	Unclear	After	O1, O2
Zhang, M., 2014 [56]	IIIa–IV	136/136	139/133	18–75	Ag-DC-CIK cells	>110^10/cycle, 4 times/cycle, 1 cycle (IV)	TP, DP	RECIST	FCM	After	O1, O2
Cheng, C., 2015 [57]	Unclear	40/40	54/26	30–73	DC-CIK cells	Unclear, 8 times/cycle, 3 cycles (IV)	TP	WHO	FCM	After	O1, O2
Li, S., 2015[42]	III–IV	26/25	25/26	70–81	DC-CIK cells	Unclear, 2 times/cycle, 2–6cycles (IV)	GP	RECIST	FCM	1 w	O1, O2
Qu, Y., 2015 [58]	IIIb–IV	50/50	62/38	36–77	DC-CIK cells	4–510^9/cycle, 4 times/cycle, 6 cycles (IV)	TP	RECIST	FCM	1 w	O1, O2
Wang, Y., 2015 [59]	Advanced	30/30	35/25	40–65	DC-CIK cells	Unclear, 8–10 times/cycle, 2 cycles (IV)	NP	Unclear	Unclear	4 w	O1, O2
Xu, H., 2015 [60]	III–IV	42/42	56/28	54–79	DC-CIK cells	DC: >110^7/time, 4 times, CIK: >110^9/time, 2 times, 2 cycles	TP	RECIST	FCM	After	O1, O2
Yang, L., 2015 [61]	IIIa–IV	36/36	47/25	38–77	DC-CIK cells	>110^10/time, 4 times/cycle, 1 cycle (IV)	TN	RECIST	FCM	2 w	O1, O2
Zhao, H., 2015[62]	II–IIIb	45/45	66/24	50–79	DC-CIK cells	510^9/time, 5 times/cycle, 4 cycles (IV)	PP	No	FCM	After	O1
Dong, Q., 2016 [63]	III–IV	26/26	28/24	52–77	DC-CIK cells	>110^10/cycle, 5 times/cycle, 4 cycles (IV)	PP	RECIST	FCM	1 w	O1, O2
Dong, Z., 2016[64]	Advanced	45/45	46/44	43–80	DC-CIK cells	1.010^9/time, 24 times/cycle, 1 cycle	NP	No	Unclear	After	O1
Wu, M., 2016 [65]	IIIb–IV	35/35	52/18	Unclear	DC-CIK cells	DC: 110^7/time (SI), CIK: 410^9/time (IV), 5 times, 4 cycles	TP	WHO	FCM	4 w	O1, O2
Yang, J., 2016[66]	IIIb–IV	60/60	54/66	Unclear	Ag-DC-CIK cells	Unclear, 1 time/cycle, 2 cycles (IV)	PP	RECIST	FCM	After	O1, O2
Yang, Y., 2016 [67]	Advanced	24/28	29/23	65–75	DC-CIK cells	>1.010^9/cycle, 6 times/cycle, 1 cycle	TP	RECIST	Unclear	After	O1
Zhang, C., 2016 [68]	IIb–IIIb	43/43	51/35	40–83	DC-CIK cells	510^9/time, 4 times/cycle, 2–6 cycles (IV)	GP	Unclear	Unclear	After	O1, O2
Zhang, Z., 2016[69]	IIIb–IV	60/60	104/16	29–82	Ag-DC-CIK cells	DC: -, 2 times, CIK: >110^8/time, 3 times/cycle, unclear (IV)	Chemo	RECIST	FCM	After	O1, O2
Wang, Y., 2017 [31]	IIIa–IV	29/30	36/23	35–76	DC-CIK cells	1.010^9/time, 8 times/cycle, 3 cycles (IV)	NP	Unclear	FCM	After	O1, O2
Zhao, H., 2017 [32]	IIIb–IV	30/30	37/23	Unclear	Ag-DC-CIK cells	DC: -, 1 time (SI); CIK: -, 1 time (IV), 2 cycles	GP	RECIST	FCM	After	O1, O2
Zhou, S., 2017 [33]	II–IV	43/43	58/28	32–70	DC-CIK cells	Unclear, 5 times/cycle, 1 cycle (IV)	GP	RECIST	FCM	After	O1, O2

Note: NSCLC: non-small-cell lung cancer; E: experimental group (DC-CIK plus chemotherapy); C: control group (chemotherapy); chemo: chemotherapy; DP: docetaxel and cisplatin; TP: paclitaxel and cisplatin; TN: paclitaxel and nedaplatin; GP: gemcitabine and cisplatin; GP: gemcitabine and platinum; NP: vinorelbine and cisplatin; PP: pemetrexed and cisplatin; ALIMTA: pemetrexed disodium for injection; GO: gemcitabine and oxaliplatin; EP: etoposide and cisplatin; IV: intravenous injection; SI: subcutaneous injection lymph node-rich region; WHO: World Health Organization guidelines for solid tumor responses; RECIST: response evaluation criteria in solid tumors; FCM: flow cytometry; Outcomes: O1: cellular immunity; O2: tumor responses.